Compare McKesson Corporation (MCK) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? McKesson Corporation trades at $832.45 (market cap $97.35B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.85. The key difference: McKesson Corporation pays a 0.39% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | VWO | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | — |
52-Week High | $995.69 | $61.24 |
52-Week Low | $659.01 | $49.54 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
VWO trades at $57.93, up 0.16% today, with a bearish technical signal from moving averages and oscillators showing neutral readings. The ETF's low expense ratio of 0.06% and a 2.4% dividend yield are key attractions, though financial ratios are unavailable. Recent news highlights emerging markets' record inflows and comparisons with competing funds, emphasizing cost advantages and exposure to developing economies.
Outlook is mixed: strong institutional interest and low costs support long-term growth in emerging markets, but bearish technicals and geopolitical risks in regions like China pose headwinds. Investors should weigh the ETF's diversification benefits against volatility from economic uncertainties and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
